ID   LAPC-4-EnzR
AC   CVCL_RA56
DR   cancercelllines; CVCL_RA56
DR   GEO; GSM2069514
DR   GEO; GSM2069515
DR   GEO; GSM2069516
DR   GEO; GSM2069517
DR   Wikidata; Q54901926
RX   PubMed=27036029;
CC   Virology: Contains an integrated xenotropic MuLV-related virus (XMRV) Bxv-1 (from parent cell line).
CC   Selected for resistance to: ChEBI; CHEBI:68534; Enzalutamide (Xtandi; MDV-3100).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (from parent cell line).
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000027.
DI   NCIt; C4863; Prostate carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_4744 ! LAPC-4
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 05-03-18; Last updated: 05-10-23; Version: 10
//
RX   PubMed=27036029; DOI=10.18632/oncotarget.8456;
RA   Kregel S., Chen J.L., Tom W., Krishnan V., Kach J., Brechka H.,
RA   Fessenden T.B., Isikbay M., Paner G.P., Szmulewitz R.Z.,
RA   Vander Griend D.J.;
RT   "Acquired resistance to the second-generation androgen receptor
RT   antagonist enzalutamide in castration-resistant prostate cancer.";
RL   Oncotarget 7:26259-26274(2016).
//